Education
About Us
Working with TipRanks
Follow Us
Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.63Last Year’s EPS
0Same Quarter Last Year
Moderate Sell
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 3.83%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights strategic global expansion and financial resilience, particularly in Europe and other international markets. However, these achievements are offset by significant challenges in the U.S. market due to generic competition and an increased net loss.Company Guidance
During Amarin Corporation's first-quarter 2025 guidance call, several key metrics highlighted the company's progress and strategic focus. The European market showed a 16% sequential quarterly growth with $5.4 million in revenue, driven by success in Spain, the U.K., and Central Eastern Europe. The company achieved reimbursement in Austria and secured access in 85% of Italy's eligible market. In the U.S., VASCEPA maintained profitability, generating $35.7 million in product revenue despite ongoing generic competition. The rest of the world saw VASCEPA's commercialization in nine markets, while efforts in China targeted a market with 330 million cardiovascular disease patients. Financially, Amarin reported a total net revenue of $42 million, with a gross margin of 59% and a net loss of $15.7 million. The company maintained a debt-free balance sheet with $282 million in cash and investments, focusing on prudent cash management and operational efficiency.Expansion of Global Reach
VASCEPA is now reimbursed in 21 countries, up from seven in 2023, and commercialized in nine rest of the world markets.
European Market Growth
VASCEPA revenues in Europe grew by 16% sequentially, driven by demand in Spain, the U.K., and Central Eastern Europe.
Strong Financial Management
The company maintained a solid cash position with $282 million in cash and no debt, keeping cash burn below 10% over the last 10 quarters.
Progress in Market Access
Secured reimbursement in Austria and launched commercially; active engagements in Norway and Ireland are ongoing.
Scientific Advancements
Nearly 100 abstracts and publications and over 150 educational initiatives since 2023 to promote the understanding of VASCEPA.
---
AMRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $10.19 | $10.18 | -0.10% |
Mar 12, 2025 | $9.41 | $8.00 | -14.98% |
Oct 30, 2024 | $12.04 | $11.59 | -3.74% |
Jul 31, 2024 | $15.65 | $13.64 | -12.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amarin Corporation Plc (AMRN) report earnings?
Amarin Corporation Plc (AMRN) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Amarin Corporation Plc (AMRN) earnings time?
Amarin Corporation Plc (AMRN) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMRN EPS forecast?
AMRN EPS forecast for the fiscal quarter 2025 (Q2) is -0.63.
---